Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

被引：11

作者：

Hamilton, E. P. ^{[1
]}

Barve, M. A. ^{[2
]}

Tolcher, A. W. ^{[3
]}

Buscema, J. ^{[4
]}

Papadopoulos, K. P. ^{[5
]}

Zarwan, C. ^{[6
]}

Anderson, C. K. ^{[7
]}

Doroshow, D. ^{[8
]}

Wang, D. ^{[9
]}

Huebner, D. ^{[10
]}

Jansen, V. M. ^{[10
]}

Jarlenski, D. ^{[10
]}

Mosher, R. ^{[10
]}

Kaufman, J. ^{[10
]}

Moore, K. N. ^{[11
]}

Richardson, D. L. ^{[11
]}

机构：

[1] Tennessee Oncol, Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA

[2] Mary Crowley Canc Res, Med Oncol, Dallas, TX USA

[3] NEXT OncologyTM, San Antonio, TX USA

[4] Arizona Oncol Associates, Oncol, Tucson, AZ USA

[5] South Texas Accelerated Res Therapeut START, Clin Res, San Antonio, TX USA

[6] Lahey Hosp & Med Ctr, Oncol, Burlington, MA USA

[7] Willamette Valley Canc Inst, Oncol, Eugene, OR USA

[8] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Hematol Oncol, New York, NY 10029 USA

[9] Henry Ford Hosp, Hematol Oncol, Detroit, MI 48202 USA

[10] Mersana Therapeut Inc, Clin Dev, Cambridge, MA USA

[11] Univ Oklahoma, Sarah Cannon Res Inst, Stephenson Canc Ctr, Gynecol Oncol Dept, Oklahoma City, OK USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.975

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

836P

引用

页码：S627 / S628

页数：2

共 50 条

[41] IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study
Lemech, C.
Sun, Y.
Nagrial, A.
Wu, X.
Morris, M.
Ning, F.
Yang, J.
Pan, Y.
Cai, J.
Lu, P.
Zhang, T.
Qiu, F.
Hu, C.
Zhang, M.
Liu, Z.
Han, G.
Nie, J.
Teng, C.
Zhou, H.
Day, D.
ANNALS OF ONCOLOGY, 2024, 35 : S360 - S360
[42] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study
Matulonis, U. A.
Moore, K. N.
Martin, L. P.
Vergote, I. B.
Castro, C.
Gilbert, L.
Malek, K.
Birrer, M. J.
O'Malley, D. M.
ANNALS OF ONCOLOGY, 2018, 29
[43] Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.
Moore, Kathleen N.
Matulonis, Ursula A.
O'Malley, David M.
Konner, Jason A.
Martin, Lainie P.
Perez, Raymond P.
Bauer, Todd Michael
Gilbert, Lucy
Seward, Shelly Marie
Oza, Amit M.
Ruiz-Soto, Rodrigo
Birrer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[44] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
O'Malley, David M.
Martin, Lainie P.
Gilbert, Lucy
Vergote, Ignace
Matulonis, Ursula A.
Birrer, Michael J.
Castro, Cesar Martin
Malek, Karim S.
Gonzalez-Martin, Antonio
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Du, Yiqun
Meng, Yanchun
Wang, Jingfen
Wang, Ying
Wu, Fan
Chen, Yu
Chen, Lilin
Qing, Lihua
Qiao, Yaya
Liu, Kezhen
Sun, Wenyi
Li, Xiaowen
Zhang, Jian
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] Luveltamab tazevibulin, an antifolate receptor alpha (FRa) antibody-drug conjugate (ADC), in combination with bevacizumab (bev) in patients with recurrent high-grade epithelial ovarian cancer (EOC): STRO-002-GM2 phase I study
Martin, L. P.
Uyar, D.
Madariaga, A.
Spira, A. I.
Oaknin, A.
Schilder, R.
Alia, E. M. Guerra
Hamilton, E. P.
Naumann, R. W.
Lorusso, D.
Lu, L.
Berman, C. J.
Borgman, A. E.
Moroney, J. W.
ANNALS OF ONCOLOGY, 2024, 35 : S568 - S569
[47] Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.
O'Malley, David M.
Moore, Kathleen N.
Vergote, Ignace
Martin, Lainie P.
Gilbert, Lucy
Martin, Antonio Gonzalez
Nepert, Dale L.
Ruiz-Soto, Rodrigo
Birrer, Michael J.
Matulonis, Ursula A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[48] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
Zhang, L.
Ma, Y.
Zhao, Y.
Fang, W. F.
Zhao, H.
Huang, Y.
Yang, Y.
Hou, X.
Wen, Z.
Zhang, S.
Wang, J.
Xiao, S.
Wang, H.
Zhu, H.
Olivo, M. S.
Zhu, Y.
ANNALS OF ONCOLOGY, 2023, 34
[49] First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01
Shimizu, Toshio
Sands, Jacob
Yoh, Kiyotaka
Spira, Alexander
Garon, Edward B.
Kitazono, Satoru
Johnson, Melissa L.
Meric-Bernstam, Funda
Tolcher, Anthony W.
Yamamoto, Noboru
Greenberg, Jon
Kawasaki, Yui
Zebger-Gong, Hong
Kobayashi, Fumiaki
Phillips, Penny
Lisberg, Aaron E.
Heist, Rebecca S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (29) : 4678 - +
[50] STRO-002-GM2: A phase 1, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody-drug conjugate (ADC), in combination with bevacizumab in patients with advanced epithelial ovarian cancer (EOC, including fallopian tube or primary peritoneal cancers).
Naumann, R. Wendel
Martin, Lainie P.
Oaknin, Ana
Spira, Alexander I.
Hamilton, Erika P.
Schilder, Russell J.
Lu, Lin
Kuriakose, Jason
Berman, Craig Jerome
Molina, Arturo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →